Real-world study backs safety of Hemlibra for acquired hemophilia A
A study in Japan found that Hemlibra, a medicine used to treat acquired hemophilia A (a rare bleeding disorder that develops later in life), appears to be safe when used alongside other medications that suppress the immune system. Acquired hemophilia A is different from the hemophilia people are born with—it happens when the body mistakenly attacks its own clotting proteins. This is the first real-world evidence supporting Hemlibra's safety for this condition in actual patients.